Published in Schizophr Bull on October 08, 2008
The environment and susceptibility to schizophrenia. Prog Neurobiol (2010) 1.94
Prenatal stress: role in psychotic and depressive diseases. Psychopharmacology (Berl) (2010) 1.29
Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. Schizophr Bull (2010) 1.13
Prenatal immune challenge is an environmental risk factor for brain and behavior change relevant to schizophrenia: evidence from MRI in a mouse model. PLoS One (2009) 1.10
Induction of Toll-like receptor 3-mediated immunity during gestation inhibits cortical neurogenesis and causes behavioral disturbances. MBio (2010) 1.10
A classification of sociomedical health indicators: perspectives for health administrators and health planners. Int J Health Serv (1976) 1.04
Immune system gene dysregulation in autism and schizophrenia. Dev Neurobiol (2012) 1.04
Prenatal exposure to infection: a primary mechanism for abnormal dopaminergic development in schizophrenia. Psychopharmacology (Berl) (2009) 1.01
Altered object-in-place recognition memory, prepulse inhibition, and locomotor activity in the offspring of rats exposed to a viral mimetic during pregnancy. Neuroscience (2011) 0.92
Olanzapine sensitization and clozapine tolerance: from adolescence to adulthood in the conditioned avoidance response model. Neuropsychopharmacology (2012) 0.91
Altering the course of schizophrenia: progress and perspectives. Nat Rev Drug Discov (2016) 0.88
Models of neurodevelopmental abnormalities in schizophrenia. Curr Top Behav Neurosci (2010) 0.88
Olanzapine treatment of adolescent rats causes enduring specific memory impairments and alters cortical development and function. PLoS One (2013) 0.86
Effects of risperidone and paliperidone pre-treatment on locomotor response following prenatal immune activation. J Psychiatr Res (2011) 0.85
Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801. Neurosci Lett (2011) 0.84
Adult response to olanzapine or clozapine treatment is altered by adolescent antipsychotic exposure: a preclinical test in the phencyclidine hyperlocomotion model. J Psychopharmacol (2013) 0.84
Long-lasting sensitization induced by repeated risperidone treatment in adolescent Sprague-Dawley rats: a possible D2 receptor mediated phenomenon? Psychopharmacology (Berl) (2013) 0.80
Maternal Immune Activation and Autism Spectrum Disorder: From Rodents to Nonhuman and Human Primates. Biol Psychiatry (2016) 0.80
Long-term impacts of adolescent risperidone treatment on behavioral responsiveness to olanzapine and clozapine in adulthood. Prog Neuropsychopharmacol Biol Psychiatry (2013) 0.79
Schizophrenia and Depression Co-Morbidity: What We have Learned from Animal Models. Front Psychiatry (2015) 0.79
Effects of prenatal immune activation and peri-adolescent stress on amphetamine-induced conditioned place preference in the rat. Psychopharmacology (Berl) (2012) 0.79
Repeated effects of the neurotensin receptor agonist PD149163 in three animal tests of antipsychotic activity: assessing for tolerance and cross-tolerance to clozapine. Pharmacol Biochem Behav (2014) 0.78
Synergistic Effect between Maternal Infection and Adolescent Cannabinoid Exposure on Serotonin 5HT1A Receptor Binding in the Hippocampus: Testing the "Two Hit" Hypothesis for the Development of Schizophrenia. ISRN Psychiatry (2012) 0.78
Adolescence as a period of vulnerability and intervention in schizophrenia: Insights from the MAM model. Neurosci Biobehav Rev (2016) 0.78
Deep brain stimulation improves behavior and modulates neural circuits in a rodent model of schizophrenia. Exp Neurol (2016) 0.77
Drug development in pediatric psychiatry: current status, future trends. Child Adolesc Psychiatry Ment Health (2012) 0.77
Animal models of prenatal immune challenge and their contribution to the study of schizophrenia: a systematic review. Braz J Med Biol Res (2012) 0.77
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts. J Med Chem (2016) 0.77
Asenapine sensitization from adolescence to adulthood and its potential molecular basis. Behav Brain Res (2014) 0.76
Antipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanisms. J Psychopharmacol (2016) 0.76
Behavioral alterations in rat offspring following maternal immune activation and ELR-CXC chemokine receptor antagonism during pregnancy: implications for neurodevelopmental psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry (2014) 0.76
Fluoxetine and aripiprazole treatment following prenatal immune activation exert longstanding effects on rat locomotor response. Physiol Behav (2012) 0.76
Differential effects of intermittent versus continuous haloperidol treatment throughout adolescence on haloperidol sensitization and social behavior in adulthood. Prog Neuropsychopharmacol Biol Psychiatry (2014) 0.76
Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophrenia. Brain Res (2015) 0.75
Positive modulation of α5 GABAA receptors in preadolescence prevents reduced locomotor response to amphetamine in adult female but not male rats prenatally exposed to lipopolysaccharide. Int J Dev Neurosci (2017) 0.75
Early neuromodulation prevents the development of brain and behavioral abnormalities in a rodent model of schizophrenia. Mol Psychiatry (2017) 0.75
The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev (2000) 17.59
Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) (2001) 5.67
Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry (2001) 5.35
Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry (2006) 4.18
Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci (2007) 4.06
Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res (2003) 3.86
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry (2005) 3.74
Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci (2003) 3.50
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A (1996) 3.28
Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology (2004) 3.17
Prediction of psychosis. A step towards indicated prevention of schizophrenia. Br J Psychiatry Suppl (1998) 2.97
Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology (1995) 2.53
Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr Bull (2005) 2.50
Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther (2003) 2.44
Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry (1999) 2.27
Prenatal infection as a risk factor for schizophrenia. Schizophr Bull (2006) 2.19
Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia. Neuropsychopharmacology (2003) 1.88
Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav Immun (2007) 1.86
Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry (2005) 1.85
Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev (2005) 1.70
Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry (2007) 1.67
Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) (1987) 1.60
The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (Berl) (2003) 1.49
Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry (2003) 1.49
Prodromal interventions for schizophrenia vulnerability: the risks of being "at risk". Schizophr Res (2005) 1.48
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr Res (2003) 1.47
The neurodevelopmental impact of prenatal infections at different times of pregnancy: the earlier the worse? Neuroscientist (2007) 1.42
Neuroscience. Maternal effects on schizophrenia risk. Science (2007) 1.29
In utero infection and adult schizophrenia. Ment Retard Dev Disabil Res Rev (2002) 1.24
Relative prenatal and postnatal maternal contributions to schizophrenia-related neurochemical dysfunction after in utero immune challenge. Neuropsychopharmacology (2007) 1.18
Early detection and intervention in schizophrenia: research. Schizophr Bull (1996) 1.15
The schizophrenia prodrome: treatment and high-risk perspectives. Schizophr Res (2002) 1.10
Psychosis treatment prior to psychosis onset: ethical issues. Schizophr Res (2001) 1.10
Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Br J Psychiatry Suppl (2007) 1.10
Treatment of the schizophrenia prodrome: is it presently ethical? Schizophr Res (2001) 1.09
Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl) (2000) 1.08
Construct validity of the animal latent inhibition model of selective attention deficits in schizophrenia. Schizophr Bull (2005) 1.08
Prenatal and postnatal maternal contributions in the infection model of schizophrenia. Exp Brain Res (2006) 1.03
Pharmacological intervention in the initial prodromal phase of psychosis. Eur Psychiatry (2005) 0.99
Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol (1999) 0.96
Can antidepressants prevent psychosis? Lancet (2007) 0.93
The expression of prepulse inhibition of the acoustic startle reflex as a function of three pulse stimulus intensities, three prepulse stimulus intensities, and three levels of startle responsiveness in C57BL6/J mice. Behav Brain Res (2005) 0.92
Neuroleptics and animal models: feasibility of oral treatment monitored by plasma levels and receptor occupancy assays. J Neural Transm (Vienna) (2008) 0.91
Prevention of schizophrenia: can it be achieved? CNS Drugs (2005) 0.90
A putative animal model of the "prodromal" state of schizophrenia. Biol Psychiatry (2005) 0.89
Impaired prepulse inhibition and prepulse-elicited reactivity but intact reflex circuit excitability in unmedicated schizophrenia patients: a comparison with healthy subjects and medicated schizophrenia patients. Schizophr Bull (2008) 0.87
Long-term haloperidol-treatment of mice: a change in beta-adrenergic receptor responsiveness. J Neural Transm (1979) 0.81
Haloperidol blood levels and clinical outcome: a meta-analysis of studies relevant to testing the therapeutic window hypothesis. J Clin Pharm Ther (1996) 0.80
Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry (2006) 0.77
Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice. Science (2013) 3.83
The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology. J Neurosci (2006) 3.03
Mesolimbic dopaminergic pathways in fear conditioning. Prog Neurobiol (2004) 2.38
Abnormal differentiation of newborn granule cells in age-related working memory impairments. Neurobiol Aging (2008) 2.38
Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav Immun (2007) 1.86
Long-term neurobehavioural impact of the postnatal environment in rats: manipulations, effects and mediating mechanisms. Neurosci Biobehav Rev (2003) 1.78
In-vivo rodent models for the experimental investigation of prenatal immune activation effects in neurodevelopmental brain disorders. Neurosci Biobehav Rev (2009) 1.74
Epidemiology-driven neurodevelopmental animal models of schizophrenia. Prog Neurobiol (2009) 1.73
Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev (2005) 1.70
Long-term effects of early-life environmental manipulations in rodents and primates: Potential animal models in depression research. Neurosci Biobehav Rev (2005) 1.70
Effect of social isolation on stress-related behavioural and neuroendocrine state in the rat. Behav Brain Res (2004) 1.65
Schizophrenia and autism: both shared and disorder-specific pathogenesis via perinatal inflammation? Pediatr Res (2011) 1.62
Enhanced recognition memory following glycine transporter 1 deletion in forebrain neurons. Behav Neurosci (2007) 1.56
Double dissociation of the effects of selective nucleus accumbens core and shell lesions on impulsive-choice behaviour and salience learning in rats. Eur J Neurosci (2005) 1.54
A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. Schizophr Bull (2008) 1.49
Hippocampal modulation of sensorimotor processes. Prog Neurobiol (2003) 1.47
Transduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats. J Virol (2004) 1.45
The neurodevelopmental impact of prenatal infections at different times of pregnancy: the earlier the worse? Neuroscientist (2007) 1.42
Dissociation of function between the dorsal and the ventral hippocampus in spatial learning abilities of the rat: a within-subject, within-task comparison of reference and working spatial memory. Eur J Neurosci (2004) 1.42
Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J Neurochem (2004) 1.38
Dorsal hippocampus and classical fear conditioning to tone and context in rats: effects of local NMDA-receptor blockade and stimulation. Hippocampus (2003) 1.35
Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry (2002) 1.28
Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov (2013) 1.27
Immunological stress at the maternal-foetal interface: a link between neurodevelopment and adult psychopathology. Brain Behav Immun (2005) 1.27
Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression. Arch Gen Psychiatry (2002) 1.24
A longitudinal examination of the neurodevelopmental impact of prenatal immune activation in mice reveals primary defects in dopaminergic development relevant to schizophrenia. J Neurosci (2010) 1.24
Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile. J Neurosci (2006) 1.23
Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res (2010) 1.22
Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: implications for brain disorders of neurodevelopmental origin such as schizophrenia. Int J Neuropsychopharmacol (2008) 1.21
GABA receptors containing the alpha5 subunit mediate the trace effect in aversive and appetitive conditioning and extinction of conditioned fear. Eur J Neurosci (2004) 1.21
Immune System and Schizophrenia. Curr Immunol Rev (2010) 1.18
Relative prenatal and postnatal maternal contributions to schizophrenia-related neurochemical dysfunction after in utero immune challenge. Neuropsychopharmacology (2007) 1.18
Specific neuronal protein: a new tool for histological evaluation of excitotoxic lesions. Physiol Behav (2002) 1.17
Neuropsychiatric disorders related to interferon and interleukins treatment. Metab Brain Dis (2008) 1.13
Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology (2007) 1.13
Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther (2011) 1.12
Performance of the marmoset monkey on computerized tasks of attention and working memory. Brain Res Cogn Brain Res (2004) 1.12
Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia. Neuropsychopharmacology (2010) 1.12
Effect of excitotoxic lesions of rat medial prefrontal cortex on spatial memory. Behav Brain Res (2002) 1.11
Prenatal immune challenge is an environmental risk factor for brain and behavior change relevant to schizophrenia: evidence from MRI in a mouse model. PLoS One (2009) 1.10
The impact of voluntary exercise on mental health in rodents: a neuroplasticity perspective. Behav Brain Res (2008) 1.09
Substance P serum levels are increased in major depression: preliminary results. Biol Psychiatry (2003) 1.08
DJ-1 and Parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice. Mol Ther (2007) 1.08
The International Society for Developmental Psychobiology annual meeting symposium: Impact of early life experiences on brain and behavioral development. Dev Psychobiol (2006) 1.08
Early deprivation and behavioral and physiological responses to social separation/novelty in the marmoset. Pharmacol Biochem Behav (2002) 1.07
Effects of typical and atypical antipsychotics on prepulse inhibition and latent inhibition in chronic schizophrenia. Biol Psychiatry (2002) 1.06
ApoE4 impairs hippocampal plasticity isoform-specifically and blocks the environmental stimulation of synaptogenesis and memory. Neurobiol Dis (2003) 1.06
Neural basis of psychosis-related behaviour in the infection model of schizophrenia. Behav Brain Res (2008) 1.05
Influence of differential housing on emotional behaviour and neurotrophin levels in mice. Behav Brain Res (2006) 1.05
Disruption of hippocampus-regulated behavioural and cognitive processes by heterozygous constitutive deletion of SynGAP. Eur J Neurosci (2010) 1.05
Early life stress: long-term physiological impact in rodents and primates. News Physiol Sci (2002) 1.03
Prenatal and postnatal maternal contributions in the infection model of schizophrenia. Exp Brain Res (2006) 1.03
Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders. Expert Rev Neurother (2006) 1.02
Age-related accumulation of Reelin in amyloid-like deposits. Neurobiol Aging (2007) 1.02
Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy. Neuropharmacology (2011) 1.02
Selective inactivation of adenosine A(2A) receptors in striatal neurons enhances working memory and reversal learning. Learn Mem (2011) 1.01
A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. Eur Arch Psychiatry Clin Neurosci (2008) 1.01
Prenatal exposure to infection: a primary mechanism for abnormal dopaminergic development in schizophrenia. Psychopharmacology (Berl) (2009) 1.01
To poly(I:C) or not to poly(I:C): advancing preclinical schizophrenia research through the use of prenatal immune activation models. Neuropharmacology (2011) 1.01
Transgenic overexpression of adenosine kinase in brain leads to multiple learning impairments and altered sensitivity to psychomimetic drugs. Eur J Neurosci (2007) 1.00
A differential involvement of the shell and core subterritories of the nucleus accumbens of rats in memory processes. Behav Neurosci (2003) 1.00
On the influence of baseline startle reactivity on the indexation of prepulse inhibition. Behav Neurosci (2008) 1.00
Dopamine-dependent neurodegeneration in rats induced by viral vector-mediated overexpression of the parkin target protein, CDCrel-1. Proc Natl Acad Sci U S A (2003) 1.00
The postweaning social isolation in C57BL/6 mice: preferential vulnerability in the male sex. Psychopharmacology (Berl) (2008) 1.00
Effect of a single maternal separation at different pup ages on the corticosterone stress response in adult and aged rats. Pharmacol Biochem Behav (2002) 0.99
Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy? Curr Pharm Des (2015) 0.99
Deprivation of parenting disrupts development of homeostatic and reward systems in marmoset monkey offspring. Biol Psychiatry (2004) 0.99
Early parental deprivation in the marmoset monkey produces long-term changes in hippocampal expression of genes involved in synaptic plasticity and implicated in mood disorder. Neuropsychopharmacology (2008) 0.99
Glycine transporter 1 as a potential therapeutic target for schizophrenia-related symptoms: evidence from genetically modified mouse models and pharmacological inhibition. Biochem Pharmacol (2011) 0.98
Effects of prenatal dexamethasone treatment on postnatal physical, endocrine, and social development in the common marmoset monkey. Endocrinology (2007) 0.98
Prenatal immune activation interacts with genetic Nurr1 deficiency in the development of attentional impairments. J Neurosci (2012) 0.98
Chronic clozapine treatment improves prenatal infection-induced working memory deficits without influencing adult hippocampal neurogenesis. Psychopharmacology (Berl) (2009) 0.97
Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci (2005) 0.97
The Effects of dizocilpine and phencyclidine on prepulse inhibition of the acoustic startle reflex and on prepulse-elicited reactivity in C57BL6 mice. Neuropsychopharmacology (2004) 0.97
Repeated parental deprivation in the infant common marmoset (Callithrix jacchus, primates) and analysis of its effects on early development. Biol Psychiatry (2002) 0.95
The role of voluntary exercise in enriched rearing: a behavioral analysis. Behav Neurosci (2006) 0.95